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Background. Treatment of late-stage human African trypanosomiasis (HAT) with melarsoprol can be improved
by shortening the regimen. A previous trial demonstrated the safety and efficacy of a 10-day treatment schedule.
We demonstrate the effectiveness of this schedule in a noncontrolled, multinational drug-utilization study.
Methods. A total of 2020 patients with late-stage HAT were treated with the 10-day melarsoprol schedule in
16 centers in 7 African countries. We assessed outcome on the basis of major adverse events and the cure rate af-
ter treatment and during 2 years of follow-up.
Results. The cure rate 24 h after treatment was 93.9%; 2 years later, it was 86.2%. However, 49.3% of patients
were lost to follow-up. The overall fatality rate was 5.9%. Of treated patients, 8.7% had an encephalopathic syndrome
that was fatal 45.5% of the time. The rate of severe bullous and maculopapular eruptions was 0.8% and 6.8%,
respectively.
Conclusions. The 10-day treatment schedule was well implemented in the field and was effective. It reduces
treatment duration, drug amount, and hospitalization costs per patient, and it increases treatment-center capacity.
The shorter protocol has been recommended by the International Scientific Council for Trypanosomiasis Research
and Control for the treatment of late-stage HAT caused by Trypanosoma brucei gambiense.
Human African trypanosomiasis (HAT; also called “sleep-
ing sickness”) ranks third among all parasitic diseases
in sub-Saharan Africa, behind malaria and filariasis [1],
in terms of disease burden as expressed in disability-
adjusted life years [2]. Sixty million people in 36 African
countries are at risk of becoming infected, and the num-
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ber of cases is estimated at 350,000. At present, only a
fraction of the population at risk is under surveillance;
therefore, the 45,000 cases reported and treated per year
may be a significant underestimation [3]. HAT is caused
by the protozoan parasite Trypanosoma brucei subspe-
cies and is transmitted by the bite of Glossina species
tsetse flies [4].
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HAT occurs in 2 distinct forms: a chronic form caused by
Trypanosoma brucei gambiense and an acute form caused by
Trypanosoma brucei rhodesiense; T. brucei gambiense causes 99.5%
of cases [1, 4]. During the early hemolymphatic disease stage,
the trypanosomes multiply in blood and lymph glands; they
then invade the central nervous system, which corresponds to
the late or meningoencephalitic disease stage. Without treat-
ment, the disease is invariably fatal.
Today, 2 drugs are available for the treatment of late-stage
HAT—eflornithine and melarsoprol. Eflornithine is difficult to
administer, requires good logistics, and is expensive to man-
ufacture. Therefore, it is of very limited use in rural treatment
centers. In addition, it is ineffective against the acute form of
the disease (caused by T. brucei rhodesiense). For these reasons
and the lack of alternatives, melarsoprol remains the drug of
choice for the treatment of late-stage HAT, even though it is
highly toxic and does not results in a 100% cure rate [5, 6]. A
major problem with melarsoprol is its long treatment schedule,
which was developed empirically; 55 years after its introduction
onto the market, regimens still vary considerably [1]. Generally,
3–4 series of 3–4 injections of increasing doses are given, spaced
with resting periods of 7–10 days. To optimize and standardize
melarsoprol treatment, an abridged 10-day protocol has been
elaborated on the basis of pharmacological investigations [7–
9], animal experiments [10], and pilot testing of patients with
HAT in the former Zaire [11]. The effectiveness of this regimen,
in terms of safety and efficacy, in comparison with a standard
treatment regimen was shown in a large-scale randomized clin-
ical trial in Angola (the Improved Application of Melarsoprol
[Impamel] I study) [12, 13]. To further assess the effectiveness
of the 10-day regimen under natural conditions, we performed
a multinational, multicenter drug-utilization study for the treat-
ment of late-stage T. brucei gambiense HAT.
PATIENTS, MATERIALS, AND METHODS
Centers and patients. The study was implemented in 16 HAT
treatment centers suggested by the respective national HAT
programs or by nongovernment organization (NGOs), where
applicable, in 7 sub-Saharan African countries where T. brucei
gambiense is endemic. The minimal conditions for the center
selection were reasonable accessibility, the availability of ret-
rospective data on HAT treatment, and the exclusive use of the
new treatment schedule for 12 consecutive months.
Study design and implementation. A very simple study de-
sign, without randomization and sample-size calculation, was
chosen to monitor the effectiveness of the 10-day treatment
schedule for melarsoprol under true field conditions (drug util-
ization; Impamel II). The enrollment period for each center was
12 months, to balance for seasonal variation. The study was
approved by the ethics committee of the 2 cantons of Basel (Eth-
ikkommission beider Basel) and the relevant ethics committees
and authorities in the respective countries. In the selected centers,
the abridged schedule was introduced as the standard treatment;
therefore, no consent was obtained from the patients.
The patient inclusion criterion was confirmed late-stage gam-
biense HAT. At present, the methodology and criteria for diag-
nosis and staging of the disease are still not standardized among
African countries; patients were included according to the staging
criteria of the respective national HAT control programs. Gen-
erally, diagnosis of late stage was made by microscopic exami-
nation of the cerebrospinal fluid (CSF) for the presence of try-
panosomes and/or an increased white blood cell (WBC) count.
Different cutoff criteria for the WBC in CSF were used: 15 cells/
mm3 in Central African Republic, Democratic Republic of
Congo, Republic of Congo, and Sudan;10 cells/mm3 in Equa-
torial Guinea; and 20 cells/mm3 in Angola and Coˆte d’Ivoire.
Treatment. Patients were treated with 2.2 mg/kg/day of
melarsoprol for 10 days, as a 3.6% solution in propylene gly-
col (Arsobal; Aventis), by slow intravenous (iv) injection. Be-
fore melarsoprol treatment, all patients received supplemen-
tary medication: antimalarials, mebendazole, multivitamins, and
paracetamol (acetaminophen). During melarsoprol treatment,
different prophylactic corticosteroid treatments were adminis-
tered: prednisolone at a dose of 1 mg/kg on days 1–7, 0.75 mg/
kg on day 8, 0.5 mg/kg on day 9, and 0.25 mg/kg on day 10 in
Democratic Republic of Congo, Equatorial Guinea, and Sudan;
1 mg/kg on days 1–9, 0.75 mg/kg on day 10, 0.5 mg/kg on day
11, and 0.25 mg/kg on day 12 in Angola; 1 mg/kg on days 1–9,
0.75 mg/kg on day 10, and 0.5 mg/kg on day 11 in Central
African Republic; 0.75 mg/kg on days 1–10 in Republic of Congo;
and 1 mL of bethamethasone in Coˆte d’Ivoire. No prednisolone
was administered, but, on days 1–10, promethazine (antihista-
mine) was given to the patients in 1 center in Democratic Re-
public of Congo (Centre Neuro-Psycho Pathologique/Cliniques
Universitaires de Kinshasa).
When an encephalopathic syndrome developed, treatment
with melarsoprol was suspended, and the patient was treated
according to national guidelines—for example, with adrenaline
(epinephrine), corticosteroids (usually hydrocortisone), and/or
diazepam. If possible, the melarsoprol treatment was resumed
after 1–3 days or was considered to have been completed if8
doses had already been given. For each patient, a case-report
form was filled out that contained information on demograph-
ic, diagnostic, and clinical characteristics before and after treat-
ment and an assessment of adverse events on a graded scale
from 0 to 2 (no, moderate, or severe reactions).
Outcome measures. Efficacy of the treatment was dem-
onstrated, by the absence of trypanosomes, by microscopic ex-
amination of the blood and/or lymph and CSF and/or a re-
duction in WBC count. Patients were scheduled for clinical
examination, including lumbar puncture (LP), 24 h after treat-
ment and every 6 months for 2 years after treatment, to monitor
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for treatment failures and relapses. Treatment failures were de-
fined as patients in whom trypanosomes could still be found
in any body fluid 24 h after treatment; relapses were defined
as patients presenting during follow-up with (1) trypanosomes
in any compartment and/or (2) an increase in CSF WBC count
to 150 cells/mm3 that was double that seen at the previous
examination or a WBC count of 6–49 cells/mm3 that was ac-
companied by clear symptoms attributed to relapse (somno-
lence, long-lasting headache, and recurrent fever). The primary
efficacy outcome was parasitological cure 24 h after treatment
(treatment failures), and the secondary efficacy outcome was
relapse within the follow-up period.
The safety of treatment was determined by the frequency of
adverse events. The primary safety outcomes were death in
temporal relation to treatment and the frequency of enceph-
alopathic syndromes. The rate of other severe adverse reactions
was defined as a secondary outcome.
Data management and statistical analysis. All data were
double entered and verified by use of EpiData 2.1 [14] software,
and analysis was done by use of the statistical software package
STATA (version 7.0; Stata). The findings were compared with
historical data from the participating centers, literature, and
the randomized clinical trial recently conducted in Angola [12,
13]. For calculation of the efficacy, the total number of all treated
patients was used as the denominator, to allow comparison
with previously reported rates.
RESULTS
Study population and baseline characteristics. A total of 2800
patients were enrolled between June 1999 and June 2002; 780
patients were not eligible for the analysis for several reasons
(figure 1). The final cohort consisted of 2020 patients who had
been correctly diagnosed and were treated with the 10-day mel-
arsoprol schedule in 10 HAT treatment centers in 5 countries.
The demographic, diagnostic, and clinical characteristics of
the patients are shown in table 1. Distributions by age, sex, and
nutritional status at the time of admission were similar among
patients at different centers. The diagnostic findings varied from
center to center, probably because of different methodologies
and cutoff criteria. The majority of patients had lymphade-
nopathies, headaches, pruritus, general weaknesses, and sleep-
ing disorders; a large variation in clinical manifestations among
the centers was evident.
Treatment compliance. The average rate of adherence to
the treatment regimen was 67.1% (1355/2020; figure 2); 78.1%
(1578/2020) finished the treatment with an interruption of !2
days. Overall, 88.8% (1793/2020) of patients received 10 doses.
Nonadherence resulted from treatment interruption due to se-
vere adverse reactions; however, in most cases, treatment was
resumed after 2–4 days (median, 2 days; mean, 4 days; SD, 4
days; range, 1–24 days). Most of the interruptions occurred
between days 8 and 10 of treatment.
Efficacy. The parasitological cure rate 24 h after treatment
was 93.9% (1897/2020; range among centers, 85.7%–100%)
(table 2). A total of 119 (5.9%) patients died during treatment,
and trypanosomes were detected in 4 (0.2%) patients who were
treated for relapse. Two years after treatment, the observed cure
rate was 86.2% (1742/2020), with considerable intercenter var-
iation (range, 70.9%–100%). Follow-up participation was highly
variable (15%–100%; data not shown). Many of the patients
who were cured at discharge did not attend any of the clinical
follow-up examinations (936/1897 [49.3%]) and were consid-
ered to have remained cured. Some 50.7% (961/1897) attended
at least 1 of 4 prescribed follow-up examinations with LP; 144
of these (7.1%) were diagnosed as having relapses. During fol-
low-up, 18 (0.9%) patients died, 7 (0.3%) after relapsing. In
53 (36.8%) of the patients who relapsed, trypanosomes were
found in blood (7 [4.9%]) or CSF (46 [31.9%]). All other re-
lapses were diagnosed by an elevated CSF WBC count of 150
cells/mm3 (61 [42.4%]) or by a CSF WBC count that had at
least doubled since discharge from the hospital that was ac-
companied by clear symptoms of disease (30 [20.8%]). Relapses
were not further analyzed, because of the large variation of the
follow-up coverage among the different centers.
Safety. The safety results are presented in table 3 by severity
and country. These results reflect the expected large variation
observed in the treatment of HAT.
During treatment, 119 patients died, an average after 9 days
of treatment (range, 1–29 days). The major causes were en-
cephalopathic syndromes, which contributed to 67.2% (80) of
the fatalities. Other causes were advanced HAT (15 [12.6%]),
concomitant diseases (10 [8.4%]), unknown etiology (9 [7.6%]),
and bullous skin reactions (5 [4.2%]).
A total of 176 (8.7%) patients had an encephalopathic syn-
drome; they generally received iv steroids at different doses. The
onset of the encephalopathic syndrome was reported after an
average of 9 days of treatment (median, 9 days; mean, 9.2 days;
range, 1–28 days). In patients who survived, treatment was
resumed after a suspension of 3 days (median, 3 days; mean,
3.2 days; range, 1–12 days). No significant seasonal variation
was observed in any of the centers (data not shown). Headache
preceded the onset of the encephalopathic syndrome in 34.1%
(60/176) and fever in 54.0% (95/176) of patients. In 22.7%
(40/176) of patients with an encephalopathic syndrome, malaria
parasites were detected during the syndrome, which probably
caused the fever in 20 (11.4%) of them. The effect of the
prophylactic use of prednisolone could only be evaluated for
2 southern Sudanese centers that provided reliable information
for each patient. In those centers, 163 (26.8%) of 607 patients
received prednisolone. Patients who did not receive prednis-
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Figure 1. Study profile of IMPAMEL II. *Seven of the patients who relapsed died during the follow-up period; their data are included in the deaths
during follow-up. TB, tuberculosis.
olone were at a slightly (statistically nonsignificant) higher risk
of developing an encephalopathic syndrome (relative risk [RR],
1.3 [95% confidence interval {CI}, 0.8–2.2]; ) or ofPp .286
dying (RR, 1.4 [95% CI, 0.5–3.9]; ).Pp .598
The frequency of skin reactions was high (28.3% [571/2020])
but varied between the centers. However, the majority of recorded
skin reactions were moderate pruritus; this was consistently not
considered to be a significant problem by the treating staff and
could be controlled with steroids or promethazine. Patients in
south Sudan who received prednisolone as prophylactic treat-
ment were at a lower risk of developing a moderate skin reaction
(RR, 0.6 [95% CI, 0.4–0.8]; ).Pp .0004
Other adverse reactions that were often reported included
fever and headache. However, these are common symptoms
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Figure 2. Compliance with treatment schedule, by country
Table 2. Short- and long-term efficacy of 10-day melarsoprol treatment (24 h after treatment and during follow-up), compared with
IMPAMEL I results, center history, and literature.
Efficacy measurement
IMPAMEL II,
10-day treatment
(n p 2020)
Center history,
standard treatment
(n p 2215)
IMPAMEL I
Literature,
standard treatment, %a
10-day treatment
(n p 250)
Standard treatment
(n p 250)
Fatalities during treatment 119 (5.9) 117 (5.3) 6 (2.4) 6 (2.4) 9.4
Treatment failures at discharge 4 (0.2) 18 (0.8) 0 (0) 0 (0) !1
Cured at time of discharge 1897 (93.9) 2080 (93.9) 244 (97.6) 239 (95.6) 90
Fatalities during follow-up 18 (0.9)b ND 6 (2.8) 8 (3.6) ND
Relapses during follow-up 144 (7.7)b 54 (2.6) 12 (5.5) 11 (4.9) !30
Lost during follow-upc 936 (49.3) ND 26 (10.7) 15 (6.3) ND
Cured 2 years after treatmentc 1742 (86.2) 2026 (91.5) 226 (90.4) 230 (92) 70–90
NOTE. Data are no. (%). ND, no data available.
a The total no. of subjects was highly variable; often, only percentages were published.
b Seven of the patients with relapse later died and are included in both categories.
c We assumed that all patients lost to follow-up were cured. We used as a denominator the total no. of all patients treated.
and signs of the disease and are not easily discriminated from
adverse events caused by treatment. Less frequently reported
reactions included polyneuropathies, diarrhea, jaundice, and
hypotension.
DISCUSSION
The present work (Impamel II) was a noncontrolled, multi-
national, multicenter drug-utilization study to evaluate, under
true field conditions, the abridged treatment schedule of mel-
arsoprol during late-stage T. brucei gambiense HAT. Because of
the very basic equipment available in treatment centers, the
often low level of staff qualifications, and the lack of experience
in the conduct of clinical trials in most centers, it was not pos-
sible to conduct a randomized study. Cluster randomization
was also considered to be impossible, because of the inherent
differences in the outcome of HAT treatment in different cen-
ters and countries and the limited number of centers available.
The 12-month enrollment period was chosen to reveal a po-
tential seasonal variation of the outcome [15]; centers that
enrolled patients for !12 months were excluded from the for-
1928 • JID 2005:191 (1 June) • Schmid et al.
Table 3. Adverse events during melarsoprol treatment, by severity and country.
Adverse event
Total
(n p 2020)
Angola
(n p 337)
Coˆte d’Ivoire
(n p 27)
Democratic
Republic of Congo
(n p 532)
Equatorial Guinea
(n p 13)
Sudan
(n p 1111)
Fatalitiesa 119 (5.9) 24 (7.1) 2 (7.4) 45 (8.5) 1 (7.7) 47 (4.2)
ES
Total 176 (8.7) 18 (5.3) 0 (0) 49 (9.2) 1 (7.7) 108 (9.7)
Grade 3 (fatal) 80 (4.0) 13 (3.9) 0 (0) 33 (6.2) 1 (7.7) 33 (3)
Case fatality rate, % 45 72 0 67 100 31
Grade 2 (coma or convulsions) 72 (3.6) 5 (1.5) 0 (0) 13 (2.4) 0 (0) 54 (4.9)
Grade 1 (psychosis) 24 (1.2) 0 (0) 0 (0) 3 (0.6) 0 (0) 21 (1.9)
Bullous eruptions
Any 30 (1.5) 7 (2.1) 0 (0) 12 (2.3) 1 (7.7) 10 (0.9)
Severe 17 (0.8) 3 (0.9) 0 (0) 8 (1.5) 0 (0) 6 (0.5)
Maculopapular eruptions
Any 228 (11.3) 31 (9.2) 9 (33.3) 58 (10.9) 1 (7.7) 129 (11.6)
Severe 138 (6.8) 25 (7.4) 7 (26.0) 45 (8.5) 0 (0) 61 (5.5)
Pruritus
Any 478 (23.7) 41 (12.2) 4 (14.8) 44 (8.3) 2 (15.4) 387 (34.8)
Severe 66 (3.2) 1 (0.3) 0 (0) 26 (4.9) 0 (0) 39 (3.5)
Motor polyneuropathy
Any 128 (6.3) 13 (3.9) 0 (0) 9 (1.7) 0 (0) 106 (9.5)
Severe 37 (1.4) 6 (1.8) 0 (0) 8 (1.5) 0 (0) 23 (2.1)
Sensitivity polyneuropathy
Any 64 (3.2) 1 (0.3) 0 (0) 4 (0.7) 0 (0) 59 (5.3)
Severe 24 (1.2) 0 (0) 0 (0) 3 (0.6) 0 (0) 21 (1.9)
Fever
Any (37.5C–39C) 653 (32.3) 39 (11.6) 24 (88.9) 109 (20.5) 2 (15.4) 479 (43.1)
Severe (139C) 233 (11.5) 17 (5.0) 11 (40.7) 53 (10.0) 1 (7.7) 151 (13.6)
Headache
Any 599 (29.6) 43 (12.8) 4 (14.8) 21 (4) 4 (30.8) 527 (47.6)
Severe 146 (7.2) 16 (4.8) 0 (0) 11 (2.1) 2 (15.4) 117 (10.5)
Diarrhea
Any 173 (8.6) 5 (1.5) 0 (0) 11 (2.1) 3 (23.1) 154 (13.9)
Severe 45 (2.2) 1 (0.3) 0 (0) 3 (0.6) 1 (7.7) 40 (3.6)
Hypotension
Any 60 (3.0) 5 (0.5) 0 (0) 23 (4.3) 0 (0) 32 (2.9)
Severe 16 (0.8) 0 (0) 0 (0) 13 (2.4) 0 (0) 3 (0.3)
Jaundice
Any 9 (0.5) 1 (0.3) 0 (0) 2 (0.4) 0 (0) 6 (0.5)
Severe 5 (0.2) 0 (0) 0 (0) 2 (0.4) 0 (0) 3 (0.2)
NOTE. Data are no. (%) of patients, unless otherwise indicated. The results are comparable to those obtained in the controlled clinical trial [12]. ES,
encephalopathic syndrome.
a All fatalities during treatment, including those due to fatal ES.
mal analysis, and data for a longer period were truncated after
the first 12 months. Other patients excluded from the formal
analysis were those who received any treatment other than 10-
day melarsoprol or who were preselected on the basis of the
self-defined criteria of a treatment center—for example, adults
only or patients admitted in good health.
The study population corresponded to the average popula-
tion of African countries [16], except for the patients treated
in Coˆte d’Ivoire ( ), who were much younger (mediannp 27
age, 15 years) than the overall study population (median age,
27 years). The clinical conditions and the diagnostic charac-
teristics of the patients at the time of admission were highly
variable among centers, which reflects the different levels of
surveillance activities in each country, the diverse qualifications
of staff and their perception of illnesses and adverse reactions
(nurses vs. medical doctors; national control programs vs. NGOs),
and differences in laboratory equipment among the centers.
However, there was no difference in the outcome of treatment
among the cohorts that were diagnosed according to the dif-
ferent cutoff criteria in use (data not shown).
The average short-term (93.9%) and long-term (86.2%) ef-
ficacies, with “all patients treated” as the denominator and con-
sidering patients who not seen during the follow-up to be cured,
were comparable to published data [5, 12, 17–22] and the
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Table 4. Severe adverse events during treatment with melarsoprol in the IMPAMEL II study, compared with standard treatment (IMPAMEL
I), center history, and literature.
Adverse event
IMPAMEL II,
10-day treatment
(n p 2020)
Center history,
standard treatment
(n p 2215)
IMPAMEL I
Literature,
standard treatment,
mean % (range)a
10-day treatment
(n p 250)
Standard treatment
(n p 250)
Fatalities 119 (5.9) 117 (5.3) 6 (2.4) 6 (2.4) 9.4 (2.7–34)
ESb 152 (7.5) 184 (8.3) 14 (5.6) 14 (5.6) 4.7 (1.5–23.5)
Grade 3 80 (4.0) 87 (3.9) 6 (2.4) 6 (2.4) 4.1 (3.3–34)
Case fatality rate, % 52.6 47.3 42.9 42.9 43.8 (33–100)
Skin reactions 166 (8.2) 35 (1.6) 23 (9.2) 13 (5.2) !3
Bullous eruptions 17 (0.8) 4 (0.2) 3 (1.2) 1 (0.4) ! 1
Maculopapular eruptions 138 (6.8) 20 (0.9) 12 (4.8) 6 (2.4) ND
Pruritus 66 (3.3) 11 (0.5) 8 (3.2) 6 (2.4) 5
Polyneuropathiesc 54 (2.7) 24 (1.1) 2 (0.8) 1 (0.4) !10
Febrile reaction 233 (11.5) 72 (3.2) 15 (6.0) 12 (4.8) 12
Headache 146 (7.2) 43 (1.9) ND ND ND
Diarrhea 45 (2.2) 19 (0.9) 6 (2.4) 4 (1.6) !25
Hypotension 16 (0.8) 19 (0.9) ND ND !1
Jaundice 5 (0.2) 3 (0.1) ND ND !3
NOTE. Data are no. (%) of patients, unless otherwise indicated. ES, encephalopathic syndrome; ND, not determined or no data available.
a The total no. of subjects was highly variable; often, only percentages were published.
b Grades 2 (convulsion or coma) and 3 (fatal).
c Motor or sensitivity polyneuropathies.
centers’ histories (table 2). This approach is somewhat unsat-
isfactory, because it leads to an overestimation of effectiveness.
The assessment of long-term efficacy is complicated by gen-
erally low follow-up rates; thus, no consistent information on
follow-up coverage is given in the literature. Our approach
yielded the best comparison to recently published studies [12,
17–23] and to the centers’ histories. The proportion of patients
in our study who attended a follow-up examination was highly
variable among centers (0%–100%). On average, one-half of
all patients attended at least 1 follow-up examination, mostly
within the first year after treatment; therefore, the failure rates
in the present study are difficult to estimate and to compare
to reported rates. The overall rate of treatment failures and
relapses in our study was 7.1% (144/2020), a value that com-
pares well with those in the literature (5%–8% [24]). However,
because alarmingly high rates—up to 30%—have been docu-
mented in some areas (Uganda [23], Angola [25], and Sudan
[26]), failure rates by disease focus should be reported more
carefully. In our study, most of the relapses (136/144) were re-
ported in southern Sudanese centers, which may be explained
(at least partially) by the enhanced follow-up activities conducted
by the executing organizations, which resulted in a 12.2% (136/
1111) failure rate in this area. However, this is still much lower
than reported rates from this area (centers’ histories, 15%–25%;
literature, 16%–24% [22]).
The safety and tolerability of the 10-day melarsoprol treatment
schedule were similar to those of standard treatment schedules
[12, 27–31], with the exception of skin reactions, fevers, and
headaches (table 4). The variability of the adverse events among
the different study centers was expectedly high, and comparable
results were found in a separate analysis of data from the patients
who had been excluded from the formal analysis. Mild symptoms
and signs such as fever (32.3%), headache (29.6%), and pruritus
(23.7%), which are also common symptoms and signs of HAT,
were more frequently reported during the study. This may be an
observation bias prompted by solicitation of information that
usually is not recorded. That more treatment interruptions
caused by moderate adverse events were reported in centers op-
erated by NGOs supports this reflection.
The frequency of treatment-related death was 5.9% (119/
2020), and the most severe reactions were encephalopathic syn-
dromes (8.7% [176/2020]). These rates are comparable to pub-
lished data [32, 33], although they are at the upper end of the
range. In accordance with the findings of previous reports [12,
27–31], encephalopathic syndromes occurred between days 1
and 28 after the initial injection of melarsoprol, with most of
them occurring between days 9 and 11 (mean, 9.2 days; SD, 4
days), which supports the view that the event is independent
of the treatment schedule and the dose applied. Also, the re-
sumption of melarsoprol after interruption and patients’ im-
provement did not result in a recurring reaction. The effect of
prednisolone prophylaxis could only be evaluated for 2 treat-
ment centers in Sudan, because other centers used dosage reg-
imens that were slightly aberrant from the study protocol, had
interruptions in drug stocks, or provided information for many
patients that was not detailed enough. In the analyzed popu-
lation, there was no statistically significant prophylactic effect
of prednisolone on the development of an encephalopathic syn-
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drome or a difference in the case-fatality rate in this cohort,
as was suggested by Pepin et al. [30]. However, with prednis-
olone treatment, we observed clear protection against the de-
velopment of moderate drug-related skin reactions [33].
The present results corroborate those of a randomized, con-
trolled clinical trial previously conducted in Angola [12]
(Impamel I) that demonstrated that a 10-day regimen was not
inferior to the lengthy standard treatment schedule. The overall
frequency of adverse events was high, but, again, there was no
increase, compared with that of standard treatment schedules,
except for skin reactions. At the time of discharge from the
hospital, symptoms and signs—such as pruritus, fever, head-
ache, tremor, weakness, and unusual behavior—had substan-
tially improved (data not shown). Also, the long-term efficacy
of our approach appeared to be equivalent to that of standard
treatment schedules [13] when follow-up activities were pur-
posely not assisted. The 10-day schedule has several advantages
over the very lengthy standard schedules: it is favorable in
socioeconomic (less drug is used and shorter hospitalizations
are required), technical (10 consecutive days and no dosage
adjustment), pharmacologic (the dosage used is the basis of all
combinations of melarsoprol in the compassionate treatment
of refractory cases), and psychological (patient and physician
compliance) terms.
Clearly, the tolerability and safety of melarsoprol are inferior
to those of eflornithine [34]. However, the administration of
eflornithine as slow infusions every 6 h over the course of 14
days is difficult and requires qualified staff and very good lo-
gistics. Therefore, eflornithine remains restricted to centers that
receive substantial and consistent support from NGOs, and the
vast majority of patients are still treated with melarsoprol.
Also, melarsoprol is still is the only treatment for T. brucei
rhodesiense, because of the inconsistent efficacy of eflornithine
against this form of the parasite. However, the use of the 10-
day melarsoprol schedule against T. brucei rhodesiense is strongly
discouraged. The clinical nature of this form is very different,
and high parasitemia levels are observed. Confirmation of the
clinical evaluation of the 10-day schedule for rhodesiense HAT
has yet to be performed.
On the basis of the results of Impamel I and II and the ex-
periences in each country, in September 2003 [35], the 10-day
melarsoprol schedule was discussed, at the request of the World
Health Organization, by the International Scientific Council for
Trypanosomiasis Research and Control and was recommended
as the standard schedule for the treatment of late-stage T. bru-
cei gambiense HAT with melarsoprol. Its use was continued after
the study in several countries (Central African Republic, Coˆte
d’Ivoire, Democratic Republic of Congo, Equatorial Guinea, and
Republic of Congo), and it is currently being implemented by
the national HAT programs.
IMPAMEL II STUDY
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tumba, Jean Kwete, Mandefu, Landu Rando Malu, Dr. Leon
Kazumba, and Bonga Nsangu; Equatorial Guinea: Dr. Mario
Sarsa, Dr. Jose Ramon Franco, and Eustaquio Nguema Ndong;
Republic of Congo: Ngondongo Philippe, Dr. Sonja van Osch,
Dr. Genevieve Kabonga, Dr. Unni Karunakara, and Dr. Diakite
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